Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17714562 | 0.77 | NOX1 (0.33) | NOX1 | |
| SCHEMBL3172947 | 0.71 | ESR1 (0.34) | MTNR1ASMYD3ESR1ESR2AR | |
| SCHEMBL13306192 | 0.69 | ESR1 (0.51) | MTNR1ASMYD3ESR1ESR2MAPT | |
| SCHEMBL30124970 | 0.69 | ESR1 (0.51) | MTNR1ASMYD3ESR1ESR2MAPT | |
| SCHEMBL5051433 | 0.69 | ESR1 (0.51) | MTNR1ASMYD3ESR1ESR2MAPT | |
| SCHEMBL13784817 | 0.69 | ESR1 (0.51) | MTNR1ASMYD3ESR1ESR2MAPT | |
| SCHEMBL5248698 | 0.68 | MTNR1A (0.38) | MTNR1ASMYD3ESR1ESR2AR | |
| SCHEMBL2590411 | 0.68 | CYP1A2 (0.47) | MAPT | |
| SCHEMBL10758515 | 0.68 | AR (0.35) | MTNR1ASMYD3ESR1ESR2AR | |
| SCHEMBL19774297 | 0.68 | MTNR1A (0.47) | MTNR1ASMYD3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050941-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050941-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | S1PR1, S1PR3, S1PR2 | MTNR1A 143/4885SMYD3 2502/4885ESR1 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.